TG Therapeutics Boosts Retail Sentiment With Q1 Revenue Beat Even As Stock Tumbles On Profit Miss, Conservative Outlook Investors are optimistic about the company’s prospects, particularly in the multiple sclerosis market, despite challenges from competitors.
TG Therapeutics Falls Short On Earnings, But Briumvi Sales Steal the Show TG Therapeutics posts Q1 profit and nearly doubles revenue, driven by rising Briumvi sales and higher full-year guidance for 2025.
TG Therapeutics Stock Tumbles After Q1 Earnings Fall Short Of Wall Street Estimates: But Retail’s Optimistic The company, however, raised its full-year 2025 global net revenue target to approximately $575 million, up from its previous guidance of $540 million.
Stock Of The Day: TG Therapeutics Breaks Out, May Head Higher TG Therapeutics has broken an important resistance level. There is a good chance that they will continue to move higher.
TG THERAPEUTICS INC (NASDAQ:TGTX), a growth stock which is not overvalued. Uncover the potential of TG THERAPEUTICS INC, a growth stock reasonably priced. NASDAQ:TGTX is excelling in growth aspects, maintaining a healthy financial position, and still offers an attractive valuation.
Bilibili, MARA And ZEEKR Are Among Top 8 Mid-Cap Gainers Last Week (Mar 3-Mar 7): Are The Others In Your Portfolio? Top mid-cap stocks jumped up to 23.87%. Some reasons include strong gold/silver, better financial results, and market strength.
Retail Bets TG Therapeutics Stock Can Sustain Post-Earnings Gains Throughout The Week Annual revenue from its MS drug, Briumvi, more than tripled, with U.S. net product revenue reaching $103.6 million in the fourth quarter and $310 million for the full year.
Stocks Pivot Lower On Trade Fears, Manufacturing Data Despite earlier indicating a strong start to March, stocks are lower this afternoon amid trade war concerns.
What's Going On With TG Therapeutics Stock Tuesday? TG Therapeutics Inc (
NASDAQ:TGTX ) shares are trading higher. The company on Tuesday provided guidance for the fourth quarter and full-year 2024.
